FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379981713> ?p ?o ?g. }

• W4379981713 endingPage "665" @default.
• W4379981713 startingPage "664" @default.
• W4379981713 abstract "Introduction: Clinical trials are important to inform decision making and to improve outcomes for patients with lymphoma. Phase II trials are designed to determine if a new treatment has enough promising efficacy and safety to warrant further investigation in a phase III trial. Randomized controlled trials have historically received the greatest consideration in providing reliable evidence of a drug's safety and efficacy. However, Single Arm Non-Randomized Studies (SANRS) have been considered as a valid option by regulators. It has been reported that 66% (49/74) of approvals granted between 1999 and 2014 from the European Medicines Agency (EMA) and U.S. Food and Drug Administration (FDA) were based on nonrandomized experiments in oncology including hematological malignancies, and lymphoma is one of the most common cancer types that has single arm FDA drug approval. The aim of this report is to evaluate the proportion and evolution in time of the use of randomization in interventional phase II clinical trials in adult patients with lymphoma, using a sample of the ClinicalTrials.govdatabase. Methods: We conducted a predefined search in the United States National Library of Medicine clinical trials database (ClinicalTrials.gov) in the field “condition or disease” for the term lymphoma with filters for interventional studies, phase 2 studies” and “adults = >18–64 years old” plus “older adults = 65 years and older”. We examined all clinical trials that met the inclusion criteria from January 1st, 2012, through December 31st, 2022. We excluded trials with overlapping terminology that did not enroll patients with mature lymphoid neoplasms, such as precursor b-lymphoblastic lymphoma/leukaemia, anaplastic lymphoma kinase (ALK) non-small-cell lung cancer and trials involving very broad disease categories such as “advanced cancer”, “hematological malignancies” or “high risk populations” with the exception when a significant proportion of patients with lymphoma was expected to be enrolled. Difficult cases were discussed and decided at the discretion of the authors. Results: Our search returned 2085 clinical trials, of those we included 1376 in the analysis according to our inclusion/exclusion criteria. We found that between 2012 and 2022 randomization was performed in 12.8% (177/1376) of interventional phase II clinical trials of adult patients with lymphoma. The histogram (Figure 1) shows that the number of trials increased during the analysis period, but the number of randomized clinical trials remained proportionally low. Keywords: therapeutics and clinical trials in lymphoma, other No conflicts of interests pertinent to the abstract." @default.
• W4379981713 created "2023-06-10" @default.
• W4379981713 creator A5045700503 @default.
• W4379981713 creator A5076375756 @default.
• W4379981713 creator A5079088688 @default.
• W4379981713 date "2023-06-01" @default.
• W4379981713 modified "2023-10-12" @default.
• W4379981713 title "RANDOMIZATION IS AN INFREQUENTLY USED METHOD IN INTERVENTIONAL PHASE II CLINICAL TRIALS OF ADULT PATIENTS WITH LYMPHOMA" @default.
• W4379981713 doi "https://doi.org/10.1002/hon.3165_513" @default.
• W4379981713 hasPublicationYear "2023" @default.
• W4379981713 type Work @default.
• W4379981713 citedByCount "0" @default.
• W4379981713 crossrefType "journal-article" @default.
• W4379981713 hasAuthorship W4379981713A5045700503 @default.
• W4379981713 hasAuthorship W4379981713A5076375756 @default.
• W4379981713 hasAuthorship W4379981713A5079088688 @default.
• W4379981713 hasBestOaLocation W43799817131 @default.
• W4379981713 hasConcept C126322002 @default.
• W4379981713 hasConcept C168563851 @default.
• W4379981713 hasConcept C177713679 @default.
• W4379981713 hasConcept C204243189 @default.
• W4379981713 hasConcept C2779338263 @default.
• W4379981713 hasConcept C31760486 @default.
• W4379981713 hasConcept C535046627 @default.
• W4379981713 hasConcept C71924100 @default.
• W4379981713 hasConceptScore W4379981713C126322002 @default.
• W4379981713 hasConceptScore W4379981713C168563851 @default.
• W4379981713 hasConceptScore W4379981713C177713679 @default.
• W4379981713 hasConceptScore W4379981713C204243189 @default.
• W4379981713 hasConceptScore W4379981713C2779338263 @default.
• W4379981713 hasConceptScore W4379981713C31760486 @default.
• W4379981713 hasConceptScore W4379981713C535046627 @default.
• W4379981713 hasConceptScore W4379981713C71924100 @default.
• W4379981713 hasIssue "S2" @default.
• W4379981713 hasLocation W43799817131 @default.
• W4379981713 hasOpenAccess W4379981713 @default.
• W4379981713 hasPrimaryLocation W43799817131 @default.
• W4379981713 hasRelatedWork W1988356095 @default.
• W4379981713 hasRelatedWork W1999967090 @default.
• W4379981713 hasRelatedWork W2041828149 @default.
• W4379981713 hasRelatedWork W2134905817 @default.
• W4379981713 hasRelatedWork W2188642196 @default.
• W4379981713 hasRelatedWork W2414969066 @default.
• W4379981713 hasRelatedWork W2586650731 @default.
• W4379981713 hasRelatedWork W2925167642 @default.
• W4379981713 hasRelatedWork W2994435929 @default.
• W4379981713 hasRelatedWork W3125097634 @default.
• W4379981713 hasVolume "41" @default.
• W4379981713 isParatext "false" @default.
• W4379981713 isRetracted "false" @default.
• W4379981713 workType "article" @default.